Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
(Repeats with no change to text) By Pamela Barbaglia and Sophie Sassard LONDON, Dec 21 (Reuters) - Chief executives got their deal-making confidence back in 2014, emboldened by a clearer outlook for their businesses to take the global value for mergers and acquisitions (M&A) to their
Read moreBy Pamela Barbaglia and Sophie Sassard LONDON, Dec 21 (Reuters) - Chief executives got their deal-making confidence back in 2014, emboldened by a clearer outlook for their businesses to take the global value for mergers and acquisitions (M&A) to their highest annual level since 2007.
Read more** A tougher pricing environment in the US along with racy valuations is causing fund managers to call time on a rally in European healthcare, the star sector performer this yr. Chart: http://link.reuters.com/cyx63w ** Sector been boosted by M&A hopes - which have been somewhat dashed, part
Read moreGENEVA, Dec 19 (Reuters) - Trials of GlaxoSmithKline's experimental Ebola vaccine are likely to move to a second phase in February, later than previously suggested, after a meeting of national regulators said they needed more information. The World Health Organization, which hosted a meeti
Read more(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks rose on Thursday, with each of the major indexes climb
Read more(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stocks rose on Thursday, with each of the major indexes climb
Read more* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s * Potentially strong competitor for Merck's Zostavax * Shares in GSK partner Agenus jump 10 percent (Adds sales figures for Merck vaccine, forecast for GSK product) By Ben Hirschler LONDON, Dec 18 (Reuters) - An
Read moreREUTERS AMERICA MORNING NEWS PLAN FOR THURSDAY DEC 18 LATEST AND PLANNED U.S. NEWS COVERAGE (ALL TIMES ET) Top stories as of 9:45 a.m. on Thursday. To find stories, search by Slug or Headline Keyword in your CMS or Advanced Search in Media Express. For story queries, pleas
Read more(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, http://link.reuters.com/mex49s; for the Morning News Call newsletter, http://link.reuters.com/nex49s) U.S. stock index futures surged on Thursday, putting the S&P 500 o
Read more
British drug-maker GlaxoSmithKline said its shareholders have given the green light to a deal with Swiss firm Novartis, which will see the two groups trade over £12.7bn of assets. The agreement, which was originally unveiled in April, will see GSK buy Novartis' vaccines business, while Novartis will
Read more** Biotechnology company's shares up 12 pct at $3.75 premarket ** Says shingles vaccine developed by partner GlaxoSmithKline Plc met main goal in a late-stage study ** The vaccine, HZ/su, combines protein found on virus that causes shingles with a component from Agenus ** Agenus
Read moreLONDON, Dec 18 (Reuters) - Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets. GSK said a meeting on Thursday had approved the transaction by an overwh
Read moreLONDON, Dec 18 (Reuters) - An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The vaccine, known as HZ/su, reduced the risk of shingles by 97
Read more* Merck-NewLink trial in Geneva halted after joint pains * Lausanne says safety data "satisfactory" in GSK vaccine trial (Adds statement on GSK Ebola vaccine, new paras 4-7) By Stephanie Nebehay GENEVA, Dec 11 (Reuters) - A clinical trial of an Ebola vaccine developed by Merck
Read more* NewLink/Merck vaccine trial paused due to joint pains * GAVI pledges up to $300 mln for 12 mln vaccine courses * Further funding of up to $90 mln to help vaccine roll-out (Wraps stories on GAVI funding, NewLink vaccine trial, adds GAVI CEO comment) By Ben Hirschler and Steph
Read more
Last checked at